Clinical trial
A Phase IV, Open Label, Multi-Centre Study to Evaluate the Safety and Tolerability of CSL Limited's Influenza Virus Vaccine in a Paediatric Population Aged >= 6 Months to < 18 Years
NCT00825162 is registered in ClinicalTrials.gov with Seqirus as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IV, Open Label, Multi-Centre Study to Evaluate the Safety and Tolerability of CSL Limited's Influenza Virus Vaccine in a Paediatric Population Aged >= 6 Months to < 18 Years
- Lead sponsor
- Seqirus
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- March 31, 2009
- Completion date
- February 28, 2010
- Enrollment
- 1,992 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
influenza